Aetion secures $11.2m in Series A funding


Aetion secures $11.2m in Series A funding

Natali_Mis / iStock

Aetion, a healthcare technology company that provides real-world evidence (RWE) analytics solutions, has secured $11.2 million in Series A funding in a round led by Flare Capital Partners and joined by Lakestar.

The Aetion Evidence Platform generates real-world evidence that allows customers to analyze virtually any real-world data to determine medical need, comparative effectiveness and the overall value profile of medical treatments and interventions.

"With the healthcare industry moving toward data-driven, value-based care, essential evidence is a necessity for assessing the expected and realized value of medical products and treatments," stated Jeremy ARassen, co-founder, president and chief scientific officer, Aetion.

"Our platform combines modern analytic methods with rapid-cycle computing technology to generate the transparent, real-time insights necessary for evaluating the outcomes and value of medical treatments and interventions."

Customers rely on the platform to provide them with the ability to gain insights into the clinical and financial status of a population, measure and compare the effectiveness and value of treatments and provider practices and realize value-based contracting. With these insights, customers can mitigate risk by monitoring product safety and effectiveness in large populations.

"Speed, efficiency, accuracy and transparency, combined with easy-to-use workflows, are critical needs when it comes to making informed decisions that impact quality patient care," said Sebastian Schneeweiss, co-founder and science lead, Aetion, and professor of medicine and epidemiology, Harvard Medical School. "The Aetion Evidence Platform delivers the best analytic science to drive decision-making, and it does so at a fraction of the cost of traditional approaches."

Aetion, Funding, Healthcare, Analytics, Flare Capital Partners, US